Mutational signatures

Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma

Aktas Samur A, Corre J, Talluri S, …, Szalat R, …, Samur MK

Journal of Clinical Oncology44(4):321-334DOI: Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple MyelomaPubMed: Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Samur MK, Roncador M, Aktas Samur A, …, Szalat R, …, Munshi NC

Blood141(14):1724-1736DOI: High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myelomaPubMed: High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Genetic Predictors of Mortality in Patients with Multiple Myeloma

Hassan H, Szalat R

The Application of Clinical GeneticsVolume 14:241-254DOI: Genetic Predictors of Mortality in Patients with Multiple MyelomaPubMed: Genetic Predictors of Mortality in Patients with Multiple Myeloma

IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WM

Bazarbachi AH, Avet-Loiseau H, Szalat R, …, Samur MK

Blood138(20):1980-1985DOI: IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WMPubMed: IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WM

Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group

Samur MK, Aktas Samur A, Fulciniti M, Szalat R, …, Munshi NC

Journal of Clinical Oncology38(27):3107-3118DOI: Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome GroupPubMed: Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group

Genomic landscape and chronological reconstruction of driver events in multiple myeloma

Maura F, Bolli N, Angelopoulos N, …, Szalat R, …, Campbell PJ

Nature Communications10(1)DOI: Genomic landscape and chronological reconstruction of driver events in multiple myelomaPubMed: Genomic landscape and chronological reconstruction of driver events in multiple myeloma

Genomic patterns of progression in smoldering multiple myeloma

Bolli N, Maura F, Minvielle S, …, Szalat R, …, Munshi N

Nature Communications9(1)DOI: Genomic patterns of progression in smoldering multiple myelomaPubMed: Genomic patterns of progression in smoldering multiple myeloma

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Walker BA, Mavrommatis K, Wardell CP, …, Szalat R, …, Morgan GJ

Blood132(6):587-597DOI: Identification of novel mutational drivers reveals oncogene dependencies in multiple myelomaPubMed: Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines

Maura F, Petljak M, Lionetti M, …, Szalat R, …, Bolli N

Leukemia32(4):1043-1047DOI: Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell linesPubMed: Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines

Genomic heterogeneity in multiple myeloma

Szalat R, Munshi NC

Current Opinion in Genetics & Development30:56-65DOI: Genomic heterogeneity in multiple myelomaPubMed: Genomic heterogeneity in multiple myeloma

High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma

Samur MK, Roncador M, Aktas-Samur A, …, Szalat R, …, Munshi NC

Blood136(Supplement 1):4-5DOI: High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma

Analysis of mutations and structural variants to redefine the genomic landscape of multiple myeloma and its clinical implications

Bolli N, Maura F, Dawson KJ, Angelopoulos N, Minvielle S, Martincorena I, et al.

Haematologica103(S3):S51-S51

Landscape of Recurrent Mutations in Non-Coding Genome with Functional Implications in Newly-Diagnosed Multiple Myeloma

Samur MK, Chakraborty C, Szalat R, …, Munshi N

Blood132(Supplement 1):190-190DOI: Landscape of Recurrent Mutations in Non-Coding Genome with Functional Implications in Newly-Diagnosed Multiple Myeloma

The apobec mutational activity in multiple myeloma: from diagnosis to cell lines

Maura F, Petljak M, Minvielle S, Szalat R, Lionetti M, Cifola I, Liang W, et al.

haematologica102(suppl. 3):124-124

Analysis of Mutational Signatures Suggest That Aid Has an Early and Driver Role in Multiple Myeloma

Maura F, Bolli N, Minvielle S, …, Szalat R, …, Munshi N

Blood128(22):116-116DOI: Analysis of Mutational Signatures Suggest That Aid Has an Early and Driver Role in Multiple Myeloma

Global Genomic Analysis of Newly Diagnosed t(4 ;14) Multiple Myeloma Reveals a Specific Mutational Spectrum and Identifies PKD2 As a Potential Therapeutic Target

Song XL, Szalat R, Talbot A, …, Bories JC

Blood128(22):4462-4462DOI: Global Genomic Analysis of Newly Diagnosed t(4 ;14) Multiple Myeloma Reveals a Specific Mutational Spectrum and Identifies PKD2 As a Potential Therapeutic Target